Cargando…

Chemotherapy-Induced Neuropathy and Diabetes: A Scoping Review

Although cancer and diabetes are common diseases, the relationship between diabetes, neuropathy and the risk of developing peripheral sensory neuropathy while or after receiving chemotherapy is uncertain. In this review, we highlight the effects of chemotherapy on the onset or progression of neuropa...

Descripción completa

Detalles Bibliográficos
Autores principales: Sempere-Bigorra, Mar, Julián-Rochina, Iván, Cauli, Omar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8395481/
https://www.ncbi.nlm.nih.gov/pubmed/34436039
http://dx.doi.org/10.3390/curroncol28040273
_version_ 1783744182500720640
author Sempere-Bigorra, Mar
Julián-Rochina, Iván
Cauli, Omar
author_facet Sempere-Bigorra, Mar
Julián-Rochina, Iván
Cauli, Omar
author_sort Sempere-Bigorra, Mar
collection PubMed
description Although cancer and diabetes are common diseases, the relationship between diabetes, neuropathy and the risk of developing peripheral sensory neuropathy while or after receiving chemotherapy is uncertain. In this review, we highlight the effects of chemotherapy on the onset or progression of neuropathy in diabetic patients. We searched the literature in Medline and Scopus, covering all entries until 31 January 2021. The inclusion and exclusion criteria were: (1) original article (2) full text published in English or Spanish; (3) neuropathy was specifically assessed (4) the authors separately analyzed the outcomes in diabetic patients. A total of 259 papers were retrieved. Finally, eight articles fulfilled the criteria, and four more articles were retrieved from the references of the selected articles. The analysis of the studies covered the information about neuropathy recorded in 768 cancer patients with diabetes and 5247 control cases (non-diabetic patients). The drugs investigated are chemotherapy drugs with high potential to induce neuropathy, such as platinum derivatives and taxanes, which are currently the mainstay of treatment of various cancers. The predisposing effect of co-morbid diabetes on chemotherapy-induced peripheral neuropathy depends on the type of symptoms and drug used, but manifest at any drug regimen dosage, although greater neuropathic signs are also observed at higher dosages in diabetic patients. The deleterious effects of chemotherapy on diabetic patients seem to last longer, since peripheral neuropathy persisted in a higher proportion of diabetic patients than non-diabetic patients for up to two years after treatment. Future studies investigating the risk of developing peripheral neuropathy in cancer patients with comorbid diabetes need to consider the duration of diabetes, cancer-induced neuropathic effects per se (prior chemotherapy administration), and the effects of previous cancer management strategies such as radiotherapy and surgery.
format Online
Article
Text
id pubmed-8395481
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-83954812021-08-28 Chemotherapy-Induced Neuropathy and Diabetes: A Scoping Review Sempere-Bigorra, Mar Julián-Rochina, Iván Cauli, Omar Curr Oncol Review Although cancer and diabetes are common diseases, the relationship between diabetes, neuropathy and the risk of developing peripheral sensory neuropathy while or after receiving chemotherapy is uncertain. In this review, we highlight the effects of chemotherapy on the onset or progression of neuropathy in diabetic patients. We searched the literature in Medline and Scopus, covering all entries until 31 January 2021. The inclusion and exclusion criteria were: (1) original article (2) full text published in English or Spanish; (3) neuropathy was specifically assessed (4) the authors separately analyzed the outcomes in diabetic patients. A total of 259 papers were retrieved. Finally, eight articles fulfilled the criteria, and four more articles were retrieved from the references of the selected articles. The analysis of the studies covered the information about neuropathy recorded in 768 cancer patients with diabetes and 5247 control cases (non-diabetic patients). The drugs investigated are chemotherapy drugs with high potential to induce neuropathy, such as platinum derivatives and taxanes, which are currently the mainstay of treatment of various cancers. The predisposing effect of co-morbid diabetes on chemotherapy-induced peripheral neuropathy depends on the type of symptoms and drug used, but manifest at any drug regimen dosage, although greater neuropathic signs are also observed at higher dosages in diabetic patients. The deleterious effects of chemotherapy on diabetic patients seem to last longer, since peripheral neuropathy persisted in a higher proportion of diabetic patients than non-diabetic patients for up to two years after treatment. Future studies investigating the risk of developing peripheral neuropathy in cancer patients with comorbid diabetes need to consider the duration of diabetes, cancer-induced neuropathic effects per se (prior chemotherapy administration), and the effects of previous cancer management strategies such as radiotherapy and surgery. MDPI 2021-08-19 /pmc/articles/PMC8395481/ /pubmed/34436039 http://dx.doi.org/10.3390/curroncol28040273 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Sempere-Bigorra, Mar
Julián-Rochina, Iván
Cauli, Omar
Chemotherapy-Induced Neuropathy and Diabetes: A Scoping Review
title Chemotherapy-Induced Neuropathy and Diabetes: A Scoping Review
title_full Chemotherapy-Induced Neuropathy and Diabetes: A Scoping Review
title_fullStr Chemotherapy-Induced Neuropathy and Diabetes: A Scoping Review
title_full_unstemmed Chemotherapy-Induced Neuropathy and Diabetes: A Scoping Review
title_short Chemotherapy-Induced Neuropathy and Diabetes: A Scoping Review
title_sort chemotherapy-induced neuropathy and diabetes: a scoping review
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8395481/
https://www.ncbi.nlm.nih.gov/pubmed/34436039
http://dx.doi.org/10.3390/curroncol28040273
work_keys_str_mv AT semperebigorramar chemotherapyinducedneuropathyanddiabetesascopingreview
AT julianrochinaivan chemotherapyinducedneuropathyanddiabetesascopingreview
AT cauliomar chemotherapyinducedneuropathyanddiabetesascopingreview